single30MG
Retatrutide
30MG Protocol
Retatrutide 30MG
Injection Freq.
Inject once weekly
Cycle Sched.
Minimum 24 weeks; trials extended to 48 weeks
Reconstitution
3.0 mL BAC water
Exceptional weight loss reported in trials (~22–24% mean at 48 weeks at higher doses)
HbA1c reduction (~1.3–2.0%) with high rates reaching HbA1c ≤6.5%
Reduced blood pressure, LDL, waist circumference
liver-fat reduction signals
Universal ≥5% responder rate reported at higher doses
1
Reconstitution Requirements
- 3.0 mL BAC water
Escalation steps: 4
Defined through week 12
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2 mg (2000 mcg) | 20 |
| 2 | Weeks 5–8 | 4 mg (4000 mcg) | 40 |
| 3 | Weeks 9–12 | 6 mg (6000 mcg) | 60 |
| 4 | Weeks 1+ | 8 mg (8000 mcg) | 80 |
Inject once weekly
Minimum 24 weeks; trials extended to 48 weeks
The Retatrutide (retatrutide) 30 mg protocol describes a triple-receptor agonist designed to address both appetite and energy expenditure. By activating GLP-1 and GIP receptors, it enhances insulin secretion when glucose is present and suppresses appetite in a manner similar to other incretin therapies. The additional glucagon receptor agonism is described as increasing metabolic rate and energy expenditure, amplifying fat oxidation and weight loss beyond GLP-1/GIP effects alone and helping counter adaptive metabolic slowing during weight reduction. The molecule is engineered with a fatty-acid moiety to extend circulation time, giving a half-life around 6 days and enabling weekly dosing. The protocol summarizes trial outcomes showing exceptional average weight loss and clinically meaningful HbA1c reductions in type 2 diabetes cohorts, as well as improvements in markers such as blood pressure, LDL cholesterol, waist circumference, and liver fat. The primary tolerability issue described is dose-dependent gastrointestinal symptoms during escalation.
Nausea
Vomiting
Diarrhea
Dose-dependent, transient GI symptoms (most common during escalation)
No severe hypoglycemia or serious treatment-related adverse events reported in cited trials
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)